dismiss

Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
Advertisement

 

advertisement

 

More Future Of...

Making the invisible visible: The future of AI in imaging Insights from Steve Tolle, vice president of global strategy and business development for IBM Watson Health

DR to meet DNA: The future of X-ray Digital X-ray will soon capture motion and provide a vast array of new insights to diagnostic imaging

The present and future of spectral imaging Insights from Christian Eusemann, Ph.D., vice president of collaborations at Siemens Healthineers North America

What will MR look like in ten years? Insights from Michael Friebe, research professor of image-guided therapies at the Otto von Guericke University in Magdeburg Germany

The future of equipment upgrades Satrajit Misra, vice president of Marketing and Strategic Development, Canon Medical Systems Inc., on what lengthening replacement cycles mean for providers

See All Future Of...  

Molecular Imaging Homepage

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

Researchers find new PET tracer that better detects melanoma than 18F-FDG 18F-P3BZA could become the new gold standard

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy Treatment for neuroendocrine tumors

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Former South African nuclear executives to appeal suspensions in court Involves monthslong shutdown of NTP Radioisotopes medical isotope plant

FDA grants Fast Track designation to 64-Cu-Dotatate Used in PET diagnostic exams for suspected neuroendocrine tumors

Editorial takes aim at NRC efforts to lower the bar for nuclear medicine providers 'The NRC has abdicated its role as a protection agency for patients' say authors

Dr. Ashok Joseph Theruvath

PET/MR and the future of pediatric chemotherapy

by John W. Mitchell , Senior Correspondent
From the March 2018 issue of DOTmed HealthCare Business News magazine

A team of researchers has demonstrated that a single PET/MR imaging protocol is effective in assessing whether pediatric cancer patients have sustained harm to their brain, heart or bones from chemotherapy treatments.

HealthCare Business News checked in with Dr. Ashok Joseph Theruvath, postdoctoral research fellow in the Molecular Imaging Program at the Stanford School of Medicine and one of the researchers, to learn more about the protocol and its potential real-world applications.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510



HCB News: Why did you develop the protocol?

Dr. Ashok Joseph Theruvath: There has been a lot of focus on finding a cure for cancer and trying to treat patients with different cancer therapy regimens. Because of higher survival rates and better treatments, we see more pediatric cancer survivors.

But the downside of chemotherapy is there are going to be side effects, especially long-term damage to healthy organs. In adults who are 60 to 70 years old [organ damage] … is not going to show up 20 or 30 years later. But in kids who have developing organs, they have a high chance to develop secondary injuries due to the chemotherapy.

So, we wanted to develop a single imaging approach that can assess the most common chemotherapy injuries. Nowadays, there are separate imaging scans for the brain and the heart. But with PET/MR, we can image all these organs in one session.

HCB News: Have discoveries made from using the PET/MR protocol had any impact on the way you think about pediatric cancer treatment?

AJT: We look for injuries after chemotherapies. So, one might think the chemotherapy should be lowered. But it's a risk/benefit analysis. On the one hand, a lower dose to avoid long-term side effects could mean the patient doesn't get cured. I think the first step is the patient gets cured, and then we think about if the dose can be lowered to get the same result.

HCB News: How does earlier detection of chemotherapy-related injuries and abnormalities impact outcomes?

AJT: In the pilot of 10 patients, the results we got were pretty good. If we can confirm these results in a larger group, then I think it will definitely have a high impact on survival rates because we can detect injuries earlier.

Brain injury incidences after chemotherapy, for example, are in about half of the kids. Heart injuries also occur in about half of the kids, and bone injuries are in 10 to 20 percent of these patients.

There are studies where you can detect heart injuries early on, so you can give beta blockers to reduce the cardiotoxicity of chemotherapies. In some patients, the bone tissues can die. If we detect the injury soon enough, we can intervene with surgery. Once the patient has symptoms of bone injury, it's irreversible.

HCB News: What is the next step you plan to take to validate this PET/MR protocol? And what are the key challenges in advancing this research?

AJT: I think we need several hundred to a thousand patients. There are not high numbers of these patients, so I think we need multiple sites and even international study to come together and upload their imaging data. Each site could answer different questions around this issue.

The PET/MR is expensive and only large academic centers have it. But most pediatric cancers are treated in large academic centers, so I think it can be done. There are now drug sensitivity tests, so if you have a patient who gets a specific cancer therapy, you can test the patient towards the drug they should get. We discuss this in our paper. So, combining these drug sensitivity tests with our PET/MR scan could be ideal.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED